AU2013352105B2 - Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors - Google Patents

Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors Download PDF

Info

Publication number
AU2013352105B2
AU2013352105B2 AU2013352105A AU2013352105A AU2013352105B2 AU 2013352105 B2 AU2013352105 B2 AU 2013352105B2 AU 2013352105 A AU2013352105 A AU 2013352105A AU 2013352105 A AU2013352105 A AU 2013352105A AU 2013352105 B2 AU2013352105 B2 AU 2013352105B2
Authority
AU
Australia
Prior art keywords
cancer
individual
telomere length
biological sample
percentile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013352105A
Other languages
English (en)
Other versions
AU2013352105A1 (en
Inventor
Ekaterina Bassett
Bart Burington
Kevin Eng
Hui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,035 external-priority patent/US9200327B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU2013352105A1 publication Critical patent/AU2013352105A1/en
Application granted granted Critical
Publication of AU2013352105B2 publication Critical patent/AU2013352105B2/en
Priority to AU2019283840A priority Critical patent/AU2019283840A1/en
Priority to AU2022202808A priority patent/AU2022202808B2/en
Priority to AU2025201333A priority patent/AU2025201333B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
AU2013352105A 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors Active AU2013352105B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019283840A AU2019283840A1 (en) 2012-11-30 2019-12-18 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2022202808A AU2022202808B2 (en) 2012-11-30 2022-04-28 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2025201333A AU2025201333B2 (en) 2012-11-30 2025-02-25 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261732263P 2012-11-30 2012-11-30
US61/732,263 2012-11-30
US201361780851P 2013-03-13 2013-03-13
US61/780,851 2013-03-13
US13/802,035 US9200327B2 (en) 2012-11-30 2013-03-13 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US13/802,035 2013-03-13
US201361798478P 2013-03-15 2013-03-15
US61/798,478 2013-03-15
US201361809228P 2013-04-05 2013-04-05
US61/809,228 2013-04-05
PCT/US2013/072302 WO2014085632A1 (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019283840A Division AU2019283840A1 (en) 2012-11-30 2019-12-18 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Publications (2)

Publication Number Publication Date
AU2013352105A1 AU2013352105A1 (en) 2015-06-18
AU2013352105B2 true AU2013352105B2 (en) 2019-09-19

Family

ID=50828470

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013352105A Active AU2013352105B2 (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2019283840A Abandoned AU2019283840A1 (en) 2012-11-30 2019-12-18 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2022202808A Active AU2022202808B2 (en) 2012-11-30 2022-04-28 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2025201333A Active AU2025201333B2 (en) 2012-11-30 2025-02-25 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019283840A Abandoned AU2019283840A1 (en) 2012-11-30 2019-12-18 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2022202808A Active AU2022202808B2 (en) 2012-11-30 2022-04-28 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
AU2025201333A Active AU2025201333B2 (en) 2012-11-30 2025-02-25 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Country Status (24)

Country Link
EP (4) EP3882355B1 (https=)
JP (2) JP6359028B2 (https=)
KR (3) KR102174763B1 (https=)
CN (2) CN104937110A (https=)
AU (4) AU2013352105B2 (https=)
BR (1) BR112015012507B1 (https=)
CA (1) CA2892445C (https=)
CY (1) CY1124140T1 (https=)
DK (2) DK3495495T3 (https=)
ES (3) ES2865446T3 (https=)
HR (2) HRP20181991T1 (https=)
HU (1) HUE054053T2 (https=)
IL (3) IL282112B (https=)
LT (2) LT2925889T (https=)
MX (1) MX362094B (https=)
NZ (2) NZ708654A (https=)
PL (2) PL3495495T3 (https=)
PT (2) PT3495495T (https=)
RS (1) RS61513B1 (https=)
SG (1) SG11201504209YA (https=)
SI (2) SI3495495T1 (https=)
SM (1) SMT202100142T1 (https=)
WO (1) WO2014085632A1 (https=)
ZA (2) ZA201900759B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3029154T (lt) 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JPWO2018207952A1 (ja) * 2017-05-12 2020-04-16 国立大学法人九州大学 発毛及び／又は育毛用組成物
KR102867725B1 (ko) 2017-07-28 2025-10-13 제론 코포레이션 골수형성이상 증후군의 치료 방법
US20200063214A1 (en) * 2018-07-31 2020-02-27 Geron Corporation Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
GB201818792D0 (en) * 2018-11-19 2019-01-02 Telonostix Ltd Compounds for telomere length-related treatment of cancer
UA130012C2 (uk) 2018-11-29 2025-10-15 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602B (zh) * 2020-09-28 2024-06-11 中国科学院上海营养与健康研究所 靶向tert在调节皮肤及毛发色素中的应用
CN115463122B (zh) * 2022-08-16 2025-03-25 吕梁学院 一种增强盐霉素抗癌活性的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135125A1 (en) * 2011-03-28 2012-10-04 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
JPH11276182A (ja) * 1997-12-26 1999-10-12 Chugai Pharmaceut Co Ltd 逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2474468C (en) 2002-01-31 2014-03-25 University Of Utah Amplifying repetitive nucleic acid sequences
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
CN100393209C (zh) 2003-09-09 2008-06-11 杰龙公司 用于端粒酶抑制的改性寡核苷酸
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
CA2602562C (en) * 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
EP1876893B1 (en) * 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
LT3029154T (lt) * 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
US9689028B2 (en) 2008-12-22 2017-06-27 University Of Utah Foundation Monochrome multiplex quantitative PCR
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135125A1 (en) * 2011-03-28 2012-10-04 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LADETTO, M. ET AL., "Telomere length correlates with histopathogenesis according to the germinal center in mature B- cell lymphoproliferative disorders.", BLOOD, (2004), vol. 103, no. 12, pages 4644 - 4649 *
WANG H. ET AL, "TELOMERE LENGTH ASSESSMENT IN HUMAN ARCHIVAL TUMOR TISSUES BY QUANTITATIVE PCR METHOD", MEETING INFO: 2ND AACR INTERNATIONAL CONFERENCE ON FRONTIERS IN BASIC CANCER RESEARCH, (2011-09-15), vol. 71, no. 18 *

Also Published As

Publication number Publication date
CY1124140T1 (el) 2022-05-27
BR112015012507A8 (pt) 2019-10-08
HK1215874A1 (en) 2016-09-23
KR102348240B1 (ko) 2022-01-10
CN111494629A (zh) 2020-08-07
SG11201504209YA (en) 2015-06-29
KR20150091491A (ko) 2015-08-11
EP3882355C0 (en) 2023-12-20
NZ748624A (en) 2020-08-28
EP3495495A1 (en) 2019-06-12
SI2925889T1 (sl) 2019-01-31
EP2925889A4 (en) 2016-06-15
EP2925889A1 (en) 2015-10-07
IL239035B (en) 2020-09-30
EP4497441A2 (en) 2025-01-29
AU2025201333B2 (en) 2025-10-16
ZA202101317B (en) 2023-03-29
DK2925889T3 (da) 2019-01-02
KR102174763B1 (ko) 2020-11-06
BR112015012507A2 (pt) 2017-07-11
EP2925889B1 (en) 2018-09-05
PT3495495T (pt) 2021-03-22
AU2022202808B2 (en) 2024-11-28
AU2019283840A1 (en) 2020-01-23
EP3495495B1 (en) 2020-12-23
IL270636B (en) 2021-04-29
ES2972330T3 (es) 2024-06-12
IL282112A (en) 2021-05-31
ES2703914T3 (es) 2019-03-13
SMT202100142T1 (it) 2021-05-07
LT2925889T (lt) 2018-12-27
ES2865446T3 (es) 2021-10-15
IL282112B (en) 2022-09-01
MX362094B (es) 2019-01-07
WO2014085632A1 (en) 2014-06-05
CA2892445C (en) 2022-06-28
ZA201900759B (en) 2020-10-28
KR20210112394A (ko) 2021-09-14
PT2925889T (pt) 2018-12-12
JP2016501523A (ja) 2016-01-21
KR20200128446A (ko) 2020-11-12
IL239035A0 (en) 2015-07-30
PL3495495T3 (pl) 2021-08-30
CN104937110A (zh) 2015-09-23
EP3882355A1 (en) 2021-09-22
JP2018099127A (ja) 2018-06-28
HUE054053T2 (hu) 2021-08-30
JP6359028B2 (ja) 2018-07-18
NZ708654A (en) 2020-04-24
AU2025201333A1 (en) 2025-03-20
AU2013352105A1 (en) 2015-06-18
RS61513B1 (sr) 2021-03-31
MX2015006538A (es) 2015-09-23
EP3882355B1 (en) 2023-12-20
PL2925889T3 (pl) 2019-02-28
LT3495495T (lt) 2021-02-25
CA2892445A1 (en) 2014-06-05
BR112015012507B1 (pt) 2023-03-07
SI3495495T1 (sl) 2021-07-30
HRP20210451T1 (hr) 2021-05-14
AU2022202808A1 (en) 2022-05-19
HRP20181991T1 (hr) 2019-03-08
DK3495495T3 (da) 2021-03-22

Similar Documents

Publication Publication Date Title
AU2022202808B2 (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9951389B2 (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
DK2898887T3 (en) Combination of telomerase inhibitor and gemcitabine for the treatment of cancer
HUE027213T2 (en) Method for identification of sensitivity of a patient to telomerase inhibition therapy
US20150344963A1 (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40062611A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40062611B (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40010121B (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40010121A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK1215874B (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40035697A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40038880B (en) Method for identification of sensitivity of a patient to telomerase inhibition therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)